Drug interactions
Crovalimab + Eculizumab
Severity: Major
Crovalimab and Eculizumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs target complement C5, but they bind different epitopes. During a switch, the two antibodies and C5 can form drug-target-drug complexes, which may trigger Type III hypersensitivity reactions such as fever, rash, arthralgia or other immune-complex manifestations.
What this interaction means in plain words
Crovalimab and Eculizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Crovalimab belongs to Miscellaneous; Eculizumab belongs to Miscellaneous.
Why it happens
Simultaneous presence of two anti-C5 antibodies with different epitopes forms circulating immune complexes with C5.
What to do
Follow the labeled switching schedule so that the dose timing is coordinated with the last eculizumab dose. Monitor closely for immune-complex reactions after the switch and manage them promptly.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Crovalimab and Eculizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Crovalimab
- Crovalimab + Ravulizumab Major
Other interactions of Eculizumab
- Eculizumab + Upadacitinib Moderate
Frequently asked questions
Can I take Crovalimab with Eculizumab?
MediHelp rates the interaction as major. Crovalimab and Eculizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs target complement C5, but they bind different epitopes. During a switch, the two antibodies and C5 can form drug-target-drug complexes, which may trigger Type III hypersensitivity reactions such as fever, rash, arthralgia or other immune-complex manifestations.
How serious is the interaction between Crovalimab and Eculizumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Follow the labeled switching schedule so that the dose timing is coordinated with the last eculizumab dose. Monitor closely for immune-complex reactions after the switch and manage them promptly.
What other medicines interact with Crovalimab?
MediHelp also lists interactions of Crovalimab with, for example, Ravulizumab. The full list is on the Crovalimab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
